skip to content »

Lester and Sue Smith Breast Center

Houston, Texas

The Lester and Sue Smith Breast Center's mission is to improve prevention, diagnosis and treatment of breast disease.
Lester & Sue Smith Breast Center
not shown on screen

C. Kent Osborne, M.D. - Publications

Selected peer-reviewed publications (from over 300 publications)

  • Hilsenbeck, S. G., Friedrichs, W. E., Schiff, R., O'Connell, P., Hansen, R. K., and Osborne, C. K. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J. Natl. Cancer Inst. 91:453-9, 1999. [PDF]
  • Harvey, J. M., Clark, G. M., Osborne, C. K., and Allred, D. C. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer. J. Clin. Oncol 17(5):1474-81, 1999. [PDF]
  • Elledge, R. M., Green, S., Pugh, R., Allred, D. C., Clark, G. M., Hill, J., Ravdin, P., Martino, S., and Osborne, C. K. ER and PgR by ligand binding assay compared with ER, PgR, and pS2 by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer. A Southwest Oncology Group Study. Intl. J. Cancer 89: 111-17, 2000. [PDF]
  • Schiff, R., Reddy, P., Ahotupa, M., Coronado-Heinsohn, El, Grim, M., Hilsenbeck, S.G., Lawrence, R., Deneke S., Herrera, R., Fuqua, S.A. W., Brown, P.H., and Osborne, C. K. Tamoxifen-stimulated breast tumor growth in vivo is associated with oxidative stress and increased AP-1 activity. J Nat Cancer Inst. 92(23):1926-34, 2000. [PDF]
  • Zhao, H.H., Herrera, R.E., Coronado-Heinsohn, E., Yang, M.C., Ludes-Meyers, J.H., Seybold-Tilson, K.J., Nawaz, Z., Yee, D., Barr, F.G., Diab, S.G., Brown, P.H., Fuqua, S.A.W., and Osborne, C. K. FKHR, a bifunctional nuclear receptor interacting protein with coactivator and corepressor functions. J. Biol. Chem. 276(30):27907-12, 2001. [PDF]
  • Osborne, C. K., Schiff, R, Fuqua, S.A.W., Shou, J. Estrogen Receptor: Current Understanding of Its Activation and Modulation. Clin. Cancer Res. 7:4338-42, 2001.
  • Osborne, C. K., Bardou, V., Hopp, T.A., Chamness, G., Hilsenbeck, S.G., Fuqua, S.A.W., Wong, J., Schiff, R., Allred, C., Clark, G.M. Role of the Estrogen Receptor Coactivator AIB1 (SRC3) and HER-2/neu in Tamoxifen Resistance in Breast Cancer. JNCI 95(5):353-61, 2003. [PDF]
  • Osborne, C. K., Pippen, J., Jones, S.E., Parker, L.M., Ellis, M., Come, S.Z., Gertler, J.T., May, J.T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R., Buzdar, A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 20(16) 3386-95, 2002. [PDF]
  • Schiff, R., Massarweh, S., Shou, J., Osborne, C. K. Breast Cancer Endocrine Resistance: How Growth Factor Signaling and Estrogen Coregulators Modulate Response. Clin. Cancer Res. 9:447s-54s, 2003.
  • Bardou, V., Arpino, G., Elledge, R., Osborne, C. K., Clark, G. Progesterone receptors status significantly improves outcome prediction over estrogen receptor alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin. Oncol 21(10): 1973-9, 2003. [PDF]
  • Morrison, A.J., Herrera, R.E., Heinsohn, E.C., Schiff, R., Osborne, C. K. Dominant Negative N-CoR Relieves Transcriptional Inhibition of Retinoic Acid Receptor but Does Not After the Agonist/Antagonist Activities of the Tamoxifen-bound Estrogen Receptor. Molec. Endocrin. 17(8):1543-54, 2003. [PDF]
  • Mauriac, L., Pippen, J.E., Quaresma Albano, J., Certler, S.Z., Osborne, C.K. Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from multicentre trials. Eur J Cancer 39(9):1228-33, 2003.
  • Schiff, R., Massarweh, S.A., Shou, J., Bharwani, L., Mohsin, S.K., Osborne, C.K. Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance. Clin Cancer Res 10(1):331s-6s, 2004.
  • Shou, J., Massarweh, S., Osborne, C.K., Wakeling, A. E, Ali, S., Schiff, R. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER-2/neu crosstalk in ER/HER2-positive breast cancer. JNCI 96(12):926-35, 2004. [PDF]
  • Howell, A., Robertson, J.F.R., Abram, P., Lichinitser, M.R., Elledge, R., Bajetta, E., Watanabe, T., Morris, C., Webster, A., Dimery, I., Osborne, C.K. Comparison of fulvestrant v. tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 22(9): 1605-13, 2004. [PDF]
  • Arpino, G., Green, S., Allred, D.C., Ravdin, R., Lew, D., Martino, S., Osborne, C.K. HER-2 amplification, EGFR expression, and tamoxifen response in ER-positive metastatic breast cancer: a Southwest Oncology Group study. Clin Can Res 10(17):5670-6. 2004. [PDF]
  • Arpino, G., Weiss, H.L., Clark, G.M., Hilsenbeck, S.G., Osborne, C.K. The Hormone Receptor Status of a Contralateral Breast Cancer is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen. JCO, in press, 2005. [PDF]
  • Osborne, C.K., Shou, J., Massarweh, S., Schiff, R. Crosstalk Between Estrogen Receptor and Growth Factor Receptor Pathways as a Cause for Endocrine Therapy Resistance in Breast Cancer. Clin Can Res 11(2):865s-70s, 2005. [PDF]
  • Osborne, C.K., Schiff, R. Aromatase Inhibitors: Future Directions. J Steroid Biochemist. 95(1-5):183-7, 2005.
  • Lippman ME, Benz C, Chinnaiyan A, Flockhart D, Harris A, Hudis C, Osborne CK, Press MF, Rae J, Sledge GW, Van't Veer L, Wicha M. Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics. Breast Cancer Res Treat. 90(1):1-3, 2005.
  • Osborne, C.K., Schiff, R., Arpino, G., Lee, A., Hilsenbeck, S.G. Endocrine Responsiveness: Understanding How Progesterone Receptor Can Be Used to Select Endocrine Therapy. Breast 14(6):458-65 2005.
  • Howell, A., Pippen, J., Elledge, R.M., Mauriac, L., Vergote, I., Jones, S.E., Come, S.E., Osborne, C.K., Robertson J.F.R. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer. Jul 15;104(2):236-9, 2005.
  • Schiff, R., Osborne, C.K. Review. Endocrine and Hormone Therapy in Breast Cancer: New insight into estrogen receptor- function and its implication for endocrine therapy resistance in breast cancer. Breast Cancer Res 7:205-11, 2005.
  • Davidson, N.E., O’Neill, A.M., Vukov, A.M., Osborne, C.K., Martino, S, White, D.R., Abeloff, M.D. Chemoendocrine Therapy for Premenopausal Women with Axillary Lymph Node – Positive, Steroid Hormone Receptor – Positive Breast Cancer: Results From INT 0101 (E5188). J Clin Oncol 23 (25), 2005.
  • Arpino, G., Weiss, H., Lee, A.V., Schiff, R., De Placido, S., Osborne, C.K., Elledge, R.M. Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance. JNCI 97(17):1254-61, 2005.
  • Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Growth factor signaling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer. 12(Suppl 1):S113-7, 2005.
  • Tham, Y.L., Gomez, L.F., Mohsin, S., Gutierrez, M.C., Weiss, H., Hilsenbeck, S.G., Elledge, R.M., Chamness, G.C., Osborne, C.K., Allred, D.C., Chang, J.C. Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat. 94(3):279-84, 2005.
  • Martin M.D., Hilsenbeck SG, Mohsin SK, Hopp TA, Clark GM, Osborne CK, Allred DC, O'Connell P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat, Oct 22:1-3, 2005.
  • Hutchins, L.F., Green, S.J., Ravdin, P.M., Lew, D., Martino, S., Abeloff, M., Lyss, A.P., Allred, D.C., Rivkin, S.E., Osborne, C.K. Randomized, controlled trial of CMF versus CAF with and without tamoxifen for high-risk, node-negative breast cancer: Treatment results of Intergroup Protocol INT-0102. JCO 23(33):8313-21, 2005.
  • Mohsin, S.K., Allred, D.C., Osborne, C.K., Cruz, A., Otto, P., Chew, H., Clark, G.M., Elledge, R.M. Morphologic and Immunophenotypic Markers as Surrogate Endpoints of Tamoxifen Effect for Prevention of Breast Cancer. Breast Cancer Res Treat. 94(3):205-11, 2005.
  • Schiff, R., Massarweh, S.A., Shou, J., Bharwani, L., Arpino, G., Rimawi, M., Osborne, C.K. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56S(7): 10-20, 2005.
  • Hilsenbeck, S.G., Elledge, R.M., Chamness, G.C., Osborne, C.K., Allred, D.C., Chang, J.C. Clinical response to neoadjuvant docetaxel predicts improve outcome in patients with large locally advanced breast cancers. Breast Cancer Res Treat 94(3):279-84, 2005.
  • Hilsenbeck, S.G., Osborne, C.K. Is There a Role for Adjuvant Tamoxifen in Progesterone Receptor-Positive Breast Cancer? An In silico Clinical Trial. Clin Cancer Res. Feb 1;12(3):1049s-55s, 2006.
  • Jiang, S., Meyer, R., Kang, K., Osborne, C.K., Wong, J., Oesterreich, S. Scaffold attachment factor SAFB1 suppresses ERa-mediated transcription in part via interaction with N-CoR. Molecular Endocrinology 20(2):311-20, 2005.
  • Cleator, S., Tsimelzon, A., Ashworth, A., Dowsett, M., Dexter, T., Powles, T., Hilsenbeck, S., Wong., H., Osborne, C.K., O’Connell, P., Chang, J.C. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 95:229-33, 2006.
  • Divisova, J., Kuiatse, I., Lazard, Z., Weiss, H., Vreeland, F., Hadsell, D.L., Schiff, R., Osborne, C.K., Lee, A.V. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 98(3):315-27, 2006.
  • Ma, X-J., Hilsenbeck, S.G., Wang, W., Ding, L. Sgroi, D.C., Bender, R.A., Osborne, C.K., Allred, D.C., Erlander, M.G. The HOXB13:IL17BR Expression Index is a Prognostic Factor in Early Stage Breast Cancer. JCO, 24(28):4611-9, 2006. [PDF]
  • Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R.. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res. 2006 Aug 15;66(16):8266-73. [PDF]
  • Martin, M.D., Hilsenbeck, S.G., Mohsin, S.K., Hopp, T.A., Clark, G.M., Osborne, C.K., Allred, D.C., O’Connell, P. Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res Treat 95(1):7-12, 2006. [PDF]
  • Wang, L.H., Yang, X.Y., Zhang, X., An, P., Kim, H.J., Huang, J., Clarke, R., Osborne, C.K., Inman, J.K., Appella, E., Farrar, W.L. Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell 10(6):487-99, 2006. [PDF]
  • Linden, H.M., Haskell, C.M., Green, S.J., Osborne, C.K., Sledge, Jr., G.W., Shapiro, C.L., Ingle, J.N., Lew, D., Hutchins, L.F., Livingston, R.B. Sequenced Compared with Simultaneous Anthracycline and Cyclophosphamide in High-Risk Stage I and II Breast Cancer: Final Analysis from INT-0137 (S9313). JCO 25(6): 656-61. [PDF]
  • Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., De Placido, D., Osborne, C.K., Schiff, R.. Eradication of ER-positive/HER2 overexpressing breast cancer xenografts with the combination of ER targeted therapy and complete blockade of the HER signaling pathway. JNCI 99(9):694-705, 2007. [PDF]
  • Friedman, L.C., Romero, C., Elledge, R., Chang, J., Kalidas, M., Dulay, M.F., Lynch, G.R., Osborne, C.K. Attribution of Blame, Self-forgiving Attitude and Psychological Adjustment in Women with Breast Cancer. J Behav Med 30(4):351-7, 2007. [PDF]
  • Chang, J.C., Makris, A., Gutierrez, C., Hilsenbeck, S.G., Hackett, J.R., Jeong, J., Liu, M-L., Baker, J., Clark-Langone, K., Baehner, F.L., Sexton, K., Mohsin, S., Gray, T., Alvarez, L., Chamness, G.C., Osborne, C.K., Shak, S. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat, 108(2):233-40. [PDF]
  • Pandya, K.J., Hu, P., Osborne, C.K., Falkson, G., Tormey, D.C.; Eastern Cooperative Oncology Group. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185). Am J Clin Oncol. 30(2):113-25, 2007. [PDF]
  • Massarweh, S., Osborne, C.K., Creighton, C., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., Schiff, R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classical estrogen receptor genomic function. Cancer Res 68(3):826-33, 2008. [PDF]
  • Arpino, G., Wiechmann, L., Osborne, C.K., Schiff, R. Cross-Talk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance. Endocr Rev. 2008 29(2):217-33. Epub ahead of print. [PDF]
  • Creighton, C.J., Osborne, C.K., van de Vijver, M., Foekens, J.A., Klijn, J., Horlings, H., Nuyten, D., Wang, Y., Zhang, Y., Chamness, C.G., Hilsenbeck, S.G., Lee, A.V., Schiff, R. Molecular profiles of progesterone receptor (PR) loss human breast tumors. Submitted Lancet.

E-mail this page to a friend